immuno-oncology

News

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform.

News

Lava fires up a $700m cancer licensing deal with Seagen

While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting

News

First human data backs Calibr/AbbVie's "switchable" CAR-T th...

California biotech Calibr and partner AbbVie have reported the first clinical data on a new CAR-T technology, which uses "switchable" cells that aim to eliminate the life-threatening side-e

Views & Analysis

IQVIA thought_leadership_spotlight header NEW 1200px

Spotlight on - The Future of Oncology Clinical Trials

We present the latest insight and analysis of the rapidly evolving field of cancer therapeutics and immuno-therapy, with a particular focus on what current innovati

News

ESMO: TIL therapy improves on Yervoy in melanoma trial

A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has been shown to be more effective at improving progression-free survival than Bristol-Myers Squibb's immuno

News

ESMO: Evidence builds for BioNTech's amplified CAR-T therapy

BioNTech has been thrust into the limelight with its mRNA-based vaccines and therapeutics – most notably its Pfizer-partnered COVID-19 shot – but the other side of its business is CAR-T the

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

Lava fires up a $700m cancer licensing deal with Seagen

First human data backs Calibr/AbbVie's "switchable" CAR-T th...

Spotlight on - The Future of Oncology Clinical Trials

ESMO: TIL therapy improves on Yervoy in melanoma trial

ESMO: Evidence builds for BioNTech's amplified CAR-T therapy

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

immuno-oncology

Editor's Picks